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Abstract 
Posterior fossa ependymoma comprises two distinct molecular entities, ependymoma_posterior fossa A (EPN_PFA) 
and ependymoma_posterior fossa B (EPN_PFB), with differentiable gene expression profiles. As yet, the response 
of the two entities to treatment is unclear. To determine the relationship between the two molecular subgroups of 
posterior fossa ependymoma and treatment, we studied a cohort of 820 patients with molecularly profiled, clini-
cally annotated posterior fossa ependymomas. We found that the strongest predictor of poor outcome in patients 
with posterior fossa ependymoma across the entire age spectrum was molecular subgroup EPN_PFA, which was 
recently reported in the paper entitled “Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa 
ependymoma in the molecular era: a retrospective multicohort analysis” in the Journal of Clinical Oncology. Patients 
with incompletely resected EPN_PFA tumors had a very poor outcome despite receiving adjuvant radiation therapy, 
whereas a substantial proportion of patients with EPN_PFB tumors can be cured with surgery alone.
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Ependymoma is the third most common pediatric brain 
tumor and can occur anywhere along the neuroaxis, 
most commonly in the posterior fossa, supratentorium, 
and spinal cord. One of the biggest challenges in pedi-
atric neuro-oncology is ependymoma of the posterior 
fossa. Posterior fossa ependymoma has a bimodal age 
distribution, with peak ages at 5 and 35 years of age [1]. 
Historically, all ependymomas were considered a single 
entity; however, over the past 10  years, it has become 
clear that ependymomas from each of the three anatomi-
cal compartments (the posterior fossa, supratentorial, 
and spinal) are distinct biological entities [2–4]. Recently, 
our group and others showed that beyond the biologi-
cal and clinical heterogeneity that are apparent within 
the anatomical compartments, there is clear heteroge-
neity within posterior fossa ependymoma [1, 3–13]. We 
showed that posterior fossa ependymoma comprises two 
distinct molecular entities called ependymoma_posterior 
fossa A (EPN_PFA) and ependymoma_posterior fossa 
B (EPN_PFB). EPN_PFA tumors occur in younger chil-
dren, result in a poor outcome, and, with the exception 
of a gain of chromosome 1q in 20% of patients, have a 
balanced copy number profile and no recurrent somatic 
nucleotide variants [3, 14]. EPN_PFA tumors have a dis-
tinct DNA methylation profile with hypermethylated loci 
converging on targets of polycomb repressor complex 2 
(PRC2) [5]. EPN_PFB tumors occur more frequently in 
old children and adults, result in a more favorable out-
come (compared with EPN_PFA tumors), and have many 
broad copy number changes with no recurrent somatic 
nucleotide variants [14].
Current therapy for posterior fossa ependymoma in 
children older than 1 year consists of maximal safe sur-
gical resection followed by 54–59  Gy of external beam 
irradiation to the tumor bed [15]. Although several trials 
of chemotherapy for posterior fossa ependymoma have 
been conducted in the past 20  years, no chemotherapy 
regimen has shown clear activity against this disease; 
however, a randomized trial of maintenance chemother-
apy by the Children’s Oncology Group (ACNS0831) is 
nearing accrual [16, 17]. Although no clear clinical risk 
stratification exists for posterior fossa ependymoma, 
incomplete surgical resection has been shown to predict 
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poor prognosis [1]. Currently, a histologic classification 
divides ependymoma into grade II and grade III; how-
ever, this classification has been shown to have very poor 
interobserver reliability, resulting in limited to no clinical 
utility [18]. As such, a new approach to the treatment and 
classification of posterior fossa ependymoma is urgently 
needed.
Recently, as reported in our Journal of Clinical Oncol-
ogy article entitled “Therapeutic impact of cytoreductive 
surgery and irradiation of posterior fossa ependymoma in 
the molecular era: a retrospective multicohort analysis” 
[19], we studied 820 patients with clinically annotated 
posterior fossa ependymoma across four independent, 
non-overlapping cohorts, including three retrospective 
cohorts and one prospective cohort. These 820 patients 
were subgrouped using the recently published methyla-
tion-based classification of ependymoma [14]. Using a 
multivariable model incorporating age, extent of surgical 
resection, postoperative first-line radiotherapy, adjuvant 
chemotherapy, and molecular subgroup, we found that 
the strongest predictor of poor outcome was EPN_PFA 
subgroup, with a hazard ratio of 2.14 (95% confidence 
interval [CI] 1.31–3.49) for progression and 4.3 (95% CI 
1.88–9.87) for death. Incomplete surgical resection and 
no adjuvant first-line radiotherapy were also associated 
with a significantly poor outcome. When we performed 
this analysis in each of the four individual cohorts, we 
found the same result, confirming the pooled analysis.
As previously described, patients with EPN_PFA 
tumors were significantly younger than patients with 
EPN_PFB tumors (no patient under 5 years of age had an 
EPN_PFB tumor), and more older patients were identi-
fied with EPN_PFB tumors [3]. To determine if EPN_PFA 
tumors are higher risk factor for relapse/progression 
across the age spectrum, first we plotted the hazard ratio 
of EPN_PFA vs. EPN_PFB across the age spectrum and 
found EPN_PFA to be a high risk factor for relapse/pro-
gression across all ages. Then, looking at EPN_PFA and 
EPN_PFB cases individually, we divided the EPN_PFA 
patients into above or equal to and below 10 years of age 
and the EPN_PFB patients into above or equal to and 
below 18 years of age. We found the prognostic implica-
tions of molecular subgroup to be independent of age at 
diagnosis.
Next, we investigated whether the previously observed 
therapeutic value of surgical cytoreduction holds true 
within each of the two subgroups. To address this, within 
each subgroup we compared progression-free survival 
rates and overall survival rates between patients who 
underwent gross total resection and those who were 
treated with subtotal resection (>5  mm residual disease 
postoperatively). When comparing gross totally resected 
cases to subtotally resected cases, we found that subtotal 
resection of EPN_PFA tumors was highly predictive of 
very poor outcome. We observed this profound differ-
ence in outcomes across all four cohorts when stratified 
by extent of surgical resection. Interestingly, sex had a 
significant influence: women with a gross total resec-
tion had a 5-year progression-free survival rate of 65.2% 
(95% CI 58.1%–73.2%), whereas men with a gross total 
resection had a 5-year progression-free survival rate of 
45.5% (95% CI 39.3%–52.7%). Both men and women who 
received a subtotal resection had a very poor outcome. 
By examining the value of postoperative first-line exter-
nal beam irradiation for EPN_PFA tumors, we found that 
irradiation in the setting of gross total resection resulted 
in a significant benefit; however, this benefit was much 
less profound in the setting of subtotal resection. We 
found that, across the entire cohort, adjuvant first-line 
chemotherapy was of little to no benefit. As such, we 
concluded that, despite the addition of external beam 
irradiation, patients with subtotally resected EPN_PFA 
tumors are at very high risk for relapse/progression and 
should be urgently prioritized to receive novel therapies.
Additionally, we investigated the role of surgery and 
irradiation in EPN_PFB tumors. Extent of resection was 
an important prognostic marker: patients with gross 
totally resected EPN_PFB tumors had a 10-year overall 
survival rate of over 90%. However, we observed a sig-
nificant difference when comparing progression-free 
survival with overall survival, suggesting that EPN_PFB 
patients can successfully receive salvage therapy at the 
time of first relapse. Strikingly, we found that a signifi-
cant proportion of patients with EPN_PFB tumors could 
be cured without external beam irradiation and with 
complete resection alone; and if they did experience a 
recurrence, they could be salvaged with external beam 
irradiation. This suggests that, after receiving irradiation, 
patients with gross totally resected EPN_PFB tumors 
have an overall survival of over 90%. Furthermore, our 
observation that some patients could be cured without 
irradiation indicates that a carefully controlled study of 
observation alone compared with radiation treatment 
after complete surgical resection needs to be done in 
patients with EPN_PFB tumors.
Finally, to predict both progression-free survival rate 
and overall survival rate, we created a risk-stratification 
nomogram of posterior fossa ependymoma that incor-
porated molecular subgroup, first-line irradiation, and 
extent of resection. This nomogram enables a far more 
robust risk-stratification analysis to help guide the next 
generation of clinical trials. Our results are in stark con-
trast to studies of medulloblastoma, in which the value 
of extent of resection was significantly dampened when 
accounting for molecular subgroup [20]. We suggest 
that complete surgical resection should be attempted in 
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all patients with posterior fossa ependymoma, including 
those with high-risk EPN_PFA tumors, and that focal 
external beam irradiation to the tumor bed should be the 
postoperative standard of care.
Conclusion and future directions
We assembled the largest-ever cohort of patients with 
posterior fossa ependymoma, and we identified a group 
of patients who were at very high risk for relapse/pro-
gression and death. Patients with subtotally resected 
EPN_PFA tumors have a very poor prognosis, and the 
key clinical goal is to develop therapies that result in 
improved outcomes. In many patients, complete resec-
tion results in significant neurological morbidity because 
of brainstem involvement, particularly in patients with 
EPN_PFA tumors. Indeed, in many instances, because 
of cranial nerve invasion and intricate brainstem inva-
sion, complete resection is impossible. Our results set the 
stage for additional studies to evaluate appropriate treat-
ment protocols for these patients. Our results suggest a 
limited role for adjuvant radiotherapy (and chemother-
apy) in patients who have incomplete tumor resection. 
Clinical trials for upfront novel therapeutics are urgently 
needed for these patients. Several candidate therapeutic 
approaches have been proposed, including epigenetic 
modifiers such as polycomb repressor complex 2 (PRC2) 
inhibition, DNA methylation inhibitors, and histone dea-
cetylase (HDAC) inhibitors, either alone or in combina-
tion. Indeed, regardless of the therapeutic approach, both 
new therapeutic approaches and rapid translation of pre-
clinical findings are needed for children with subtotally 
resected EPN_PFA tumors. Considering the very poor 
outcomes of this group with the current standard of care, 
novel therapeutics should be prioritized upfront, rather 
than at the time of progression or recurrence, to rapidly 
determine activity against the residual disease.
Our data suggest that a significant proportion of ado-
lescents and adults with EPN_PFB tumors can be cured 
without external beam irradiation. Given the signifi-
cant negative effects that external beam irradiation has 
on learning and memory, a carefully conducted clinical 
trial of observation alone for completely resected EPN_
PFB tumors should be considered. This will have to be a 
multinational effort, likely requiring close cooperation 
between adult and pediatric cooperative groups, since 
most adults with ependymoma are not treated on open 
protocols.
The current generation of clinical trials for epend-
ymoma, which were designed over a decade ago, still 
consider all ependymomas to be one entity and do not 
incorporate any molecular stratification. Considering the 
profound clinical and therapeutic differences observed 
in our study, molecularly informed clinical trials for 
posterior fossa ependymomas are urgently needed to 
prioritize novel therapies for patients at high risk, while 
minimizing the adverse effects of treatment for those 
patients at low risk.
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